Home › Acute Lymphoblastic Leukemia › NCT06446661

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

Improving Oral Chemotherapy Adherence in Maintenance for Adolescents and Adults With Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Using Text Messages

Who can join

Ages 15 and older · All sexes

Inclusion Criteria:

* Age of 15 years or older at time of enrollment
* Diagnosed with ALL or T-cell lymphoblastic lymphoma
* Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance. Patients in the pilot phase may have already started maintenance as long as the end of their maintenance therapy is scheduled to occur after the end of the 28-day pilot intervention.

Exclusion Criteria:

* Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages
* Patient does not wish to participate
* Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.

About the study

This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.

What is being tested

• High Intensity (other)
• No Text Messagings (other)
• Low Intensity Text Messaging (other)

Sponsor: University of Chicago · Participants: 48 · Started: May 19, 2026

Contact the study team

• Clinical Trials Intake · Phone: 1-855-702-8222

Official record on ClinicalTrials.gov — NCT06446661

Locations in the U.S.

Conditions

• Acute Lymphoblastic Leukemia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.